Our proven technology makes innovative therapies possible
Our hydrogel
ELUTYXTM - Bioresorbable, Sustained Drug Delivery
Our proprietary ELUTYX hydrogel technology is designed for sustained and localized drug delivery aiming to maximize therapeutic efficacy while minimizing systemic exposure1-5
Clinically Proven
Established hydrogel platform6,7
Continuous and Consistent Delivery
Versatile
Biocompatible and tunable for use in multiple locations within the eye8-10
Discover our pipeline
References
1. Sawhney AS, et al., Inventors, Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US Patent 8,409,606 B2. April 2, 2013. 2. Blizzard C, et al. Clin Ophthalmol. 2021:15 2055–2061. 3. Boyer DS, et al. Presented at the American Academy of Ophthalmology Annual Meeting; Virtual; November 13-15, 2020. 4. Goldstein MH, et al. Invest Ophthalmol Vis Sci. 2020;61(7):4266. 5. McGrath M, et al. Invest Ophthalmol Vis Sci. 2014;55:472. 6. Walters T, et al. J Clin Exp Ophthalmol. 2016;7(4):1-11. 7. Tyson SL, et al. J Cataract Refract Surg. 2019;45(2):204-212. 8. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2025. 9. Patel C, et al. Invest Ophthalmol Vis Sci. 2023;64(8):4299. 10. Moshfeghi AA, et al. Invest Ophthalmol Vis Sci. 2023;64(8):936.